Videos

The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.

The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.

Susan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the panel discussion she participated in at BIO 2022.

Michael Parini, chief executive officer and director, Freeline Therapeutics, discussed the company’s pipeline and mission.

The senior vice president of clinical development at Passage Bio discussed intracisternal magna administration of PBGM01.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.

Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.

The director of the Center for Multiple Myeloma at Mass Gen discussed current CAR T-cell therapies in multiple myeloma.

Jan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.

The vice-chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center discussed more work to be done with CAR T-cell therapies.

Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.

The director of the Alleghany Health Network Institute of Cellular Therapeutics discussed islet cell transplant for the treatment of chronic pancreatitis.

Jason Westin, MD, FACP, leader, DLBCL research team, MD Anderson Cancer Center, discussed results from the ZUMA-7 trial at ASCO 2022.

Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.

The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.

The associate professor of medicine at Medical College of Wisconsin discussed advantages of the ARC-SparX platform.

The cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.

The renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.

Stefan Braam, PhD, chief executive officer of Ncardia and Cellistic discussed the companies’ work in the cell therapy space.

The director of the Center for Multiple Myeloma and Mass Gen discussed unmet needs with CAR T-cell therapy in multiple myeloma.

The vice president of neuroscience at Sangamo Therapeutics discussed identifying novel capsids with improved neuronal transduction to the CNS.

The chief scientific officer of Sangamo Therapeutics discussed the first-in-human STEADFAST trial.

The director of the Liver Tumor Program at Texas Children’s Hospital discussed a phase 1 study of CAR NK T-cells in neuroblastoma.

The senior investigator from NINDS discussed findings investigating serious AEs across different trials.

The clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.